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Abstract
Background: For cachectic patients with chronic respiratory disease (CRD), conventional enteral
nutrition formula is an optional treatment to maintain energy balance. The molecular mechanisms
by which enteral nutrition formula controls appetite and weight remain unknown. We examined
whether enteral nutrition formula rich in octanoic acids would increase plasma levels of ghrelin, an
appetite-stimulating hormone produced in the stomach, in cachectic patients with CRD.
Methods: Plasma ghrelin profiles in cachectic patients with CRD were assessed and compared
with those in age- and sex-matched controls. Plasma levels of acyl-ghrelin, an active ghrelin modified
by octanoic acids, and desacyl-ghrelin were measured separately. We examined changes in 24-h
plasma ghrelin profiles before and after single administration of the formula. We also evaluated the
effects of 2-week administration of the formula on plasma ghrelin levels and nutritional status in
patients.
Results: The ratio of acyl-ghrelin to desacyl-ghrelin in plasma was lower in patients than in
controls. Single administration of the formula did not change plasma desacyl-ghrelin levels, but
induced an increase in acyl-ghrelin levels. Two-week treatment with the formula was effective in
increasing weight and acyl-ghrelin, along with improving nutritional status in patients.
Conclusion: These results show that the formula contributes to increased weight, which may be
associated with induction of acyl-ghrelin production in cachectic patients with CRD.
Background
Weight loss and nutritional depletion represent inde-
pendent risk factors for the incidence of pneumonia and
mortality in patients with chronic respiratory diseases
(CRD) [1,2]. Excess energy expenditure and appetite loss
are the main causes of weight loss in such patients, and are
difficult to control using established treatments. Enteral
nutrition formula is often used as a supplement for
patients with insufficient oral calorific intake, although
the effects of additional nutrition on weight gain seem to
differ depending on the components of supplementation
[3,4]. The contribution of formula components to weight
gain and to induction of orexigenic hormones remains
unclear.
Ghrelin, a novel growth hormone (GH)-releasing peptide,
was first isolated from the stomach [5] and induces a pos-
itive energy balance by stimulating food intake through
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GH-independent mechanisms. Acyl-ghrelin, an active
ghrelin that induces appetite through the hypothalamus,
is synthesized in the stomach and inactivated as desacyl-
ghrelin by deacylation. Octanoic acids are essential for
acylation in the biosynthesis of acyl-ghrelin. Increased
intake of octanoic acids may thus increase plasma acyl-
ghrelin levels. Many reports have provided molecular
analysis of ghrelin in patients with malignancy, but few
have analyzed ghrelin levels in cachectic patients with
CRD.
Based on the hypothesis that octanoic acids are necessary
for acylation in biosynthesis of acyl-ghrelin, we investi-
gated whether oral administration of an octanoic acid-rich
formula would increase plasma acyl-ghrelin levels in
cachectic patients with CRD.
Methods
Participants
We recruited 4 inpatients (2 women, 2 men; age range,
62–72 y; 2 smokers, 2 ex-smokers; duration of the illness,
2–5 y; BMI, 15.8 ± 1.7) and 19 outpatients (8 women, 11
men; age range, 62–78 y; 7 smokers, 12 ex-smokers; dura-
tion of illness, 1–10 y; BMI, 16.0 ± 2.0) with CRD. Under-
lying pathology was bronchiectasis in 2 and 7 patients,
COPD in 1 and 7 patients, and old pulmonary tuberculo-
sis in 1 and 5 patients, respectively. At enrolment, the fol-
lowing inclusion criteria were applied: i) stable respiratory
disease for >6 months; and ii) cachexia with complaints of
appetite loss. The following exclusion criteria were
adopted: i) treatment with steroids, immunosuppressants
or antibiotics prescribed within 3 months prior to the
study; or ii) presence of pneumonia, cancer or asthma.
Cachectic patients were defined as those with docu-
mented nonedematous and nonintentional weight loss
>7.5% of previous normal weight over a period of ≤ 6
months and body mass index (BMI) <21 at entry. All
patients provided written informed consent for participa-
tion and the Research Ethics Committee of Miyazaki Uni-
versity approved all study protocols in advance.
Study protocol
The present study set 2 protocols, as described below.
First, we investigated the difference in 24-h profiles for
plasma ghrelin levels with and without administration of
an enteral nutrition formula rich in octanoic acids using 4
inpatients with CRD on admission. The enteral nutrition
formula used here provides 3.0 g of octanoic acid triglyc-
eride and 400 kcal per 400 ml (EN Otsuka, Naruto,
Japan). The formula was prepared to provide 2.8 g/day of
octanoic acid to patients when tricaprylin hydrolyzed by
lipase and free octanoic acid become 100% detached. On
day 1, blood samples were taken from the 4 inpatients
with calorie intake limited to 1,800 kcal/day. On day 2,
400 ml of the formula was administered between break-
fast and lunch in addition to meals providing 1,800 kcal.
Blood samples were drawn at 07:00, 09:00, 12:00, 14:00,
17:00, 19:00 and 21:00 to identify 24-h profiles of plasma
ghrelin levels. As a second trial, 400 ml/day of formula
was orally administered to 19 outpatients for 2 weeks.
Body weights of patients were measured at baseline and
after 2 weeks of formula administration. Blood samples
for these patients were taken on an empty stomach before
breakfast to evaluate nutrition status and plasma ghrelin
levels at baseline and after 2 weeks of formula administra-
tion. Ten age- and sex-matched healthy volunteers were
Table 1: Changes in parameters before and after 2-week once daily oral administration of octanoic acid formula to cachectic patients 
with chronic respiratory disease.
Before After
body mass index (kg/m2) 16.0 ± 2.00 16.3 ± 2.00 p < 0.05
appetite score 40 ± 22 64 ± 27 p < 0.05
acyl-ghrelin (fmol/ml) 11.0 ± 11.1 14.8 ± 7.20 p < 0.05
desacyl-ghrelin (fmol/ml) 90.1 ± 52.4 90.9 ± 52.5 NS
total protein (g/dl) 6.9 ± 0.6 7.3 ± 0.7 p < 0.05
albumin (g/dl) 3.8 ± 0.4 4.0 ± 0.4 p < 0.05
total cholesterol (mg/dl) 181 ± 40 184 ± 210 NS
fasting glucose (mg/dl) 94 ± 9 91 ± 90 NS
prealbumin (mg/dl) 15.8 ± 4.20 17.9 ± 3.90 p < 0.05
transferrin (mg/dl) 198 ± 41 231 ± 570 p < 0.05
retinol binding protein (mg/dl) 1.9 ± 0.4 2.3 ± 0.5 p < 0.05
adrenalin (pg/ml) 63 ± 40 60 ± 21 NS
noradrenalin (pg/ml) 852 ± 320 724 ± 298 NS
dopamine (pg/ml) 24 ± 10 18 ± 60 NS
GH (ng/ml) 1.2 ± 1.0 1.3 ± 1.1 NS
IGF-1 (ng/ml) 87 ± 36 98 ± 39 p < 0.05
Age: range 62–78 y; sex:8 women, 11 men; oral 400 ml octanoic acid formula administered once daily after breakfast in addition to food intake of 
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recruited as controls to compare ghrelin levels with those
in cachectic patients at baseline. Mean BMI was signifi-
cantly higher in controls (20.4 ± 5.7) than in patients (p <
0.05).
Blood sampling and assay
Blood samplings were performed at baseline and during
the week after the end of therapy to measure levels of total
protein, albumin, glucose, total cholesterol, triglycerides
and rapid-turnover proteins. Blood samples were taken
from an antecubital vein after 30-min bed rest in the
morning following an overnight fast. Plasma acyl-ghrelin
and desacyl-ghrelin levels were measured by enzyme-
linked immunosorbent assay (Mitsubishi Kagaku Iatron,
Tokyo, Japan). Immunoradiometric assays were used to
measure levels of serum GH (Ab Bead HGH Eiken; Eiken
Chemical, Tokyo, Japan) and insulin-like growth factor
(IGF)-1 (Somatomedin CII Bayer; Bayer Medical, Tokyo,
Japan).
Appetite assessment
Appetite in patients was quantified using the Edmonton
Symptom Assessment Scale [6], which uses a 100-mm vis-
ual analog scale for appetite. Before and after 2-week
administration of formula, appetite in patients was
assessed before breakfast between 08:00 and 09:00.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Comparison of ghrelin levels between the 2 groups was
analyzed using the Mann-Whitney U test. Changes in
parameters between the 2 groups were analyzed using the
Wilcoxon signed-rank test. Values of p < 0.05 were taken
to indicate statistical significance.
Results
Plasma ghrelin levels in patients with chronic pulmonary 
disease at study entry
Plasma acyl-ghrelin and desacyl-ghrelin levels were 11.0 ±
11.1 fmol/ml and 90.1 ± 52.4 fmol/ml, respectively, in
the 19 outpatients with CRD (Table 1). Acyl-ghrelin levels
trended to be lower and desacyl-ghrelin levels to be higher
in patients than in controls (patients: 15.1 ± 12.9 fmol/
ml; range, 4.0–42.5 fmol/ml and controls: 68.7 ± 62.0
fmol/ml; range, 20.5–197.5 fmol/ml, respectively),
although no significant differences were identified. The
sum of both forms of ghrelin was higher in patients
(101.1 ± 58.8 fmol/ml) than in controls (83.7 ± 74.3
fmol/ml). The ratio of plasma acyl-ghrelin to desacyl-
ghrelin was lower in patients (0.15 ± 0.16) than in con-
trols (0.24 ± 0.10).
Ghrelin 24-h profiles with and without single 
administration of formula
Plasma ghrelin levels peaked in the early morning and
decreased after meals, supporting the findings of previous
reports (Figure 1). Plasma desacyl-ghrelin levels with for-
mula resembled those with no formula administration,
while single administration of 400 ml of formula between
breakfast and lunch induced higher acyl-ghrelin levels
before dinner, remaining high until the next morning.
Effect of 2-week administration of formula on plasma 
ghrelin, appetite, weight, nutrition status and hormone 
levels
Significant increases were seen in levels of plasma acyl-
ghrelin, appetite score and body weight, but not desacyl-
ghrelin. Levels of serum total protein, albumin and rapid
turnover proteins increased after two-week administra-
tion of formula. No correlations were identified between
the increases in acyl-ghrelin levels and weight or nutrition
parameters. Two-week administration of formula did not
alter fasting glucose, total cholesterol, triglyceride, cate-
cholamines or GH levels, but induced an increase in
serum IGF-1 levels.
Discussion
This is the first paper showing a molecular analysis of
plasma ghrelin in cachectic patients with CRD. Ghrelin
24-h profiles of plasma acyl-ghrelin (upper) and desacyl-ghre- lin (lower) Figure 1
24-h profiles of plasma acyl-ghrelin (upper) and desa-
cyl-ghrelin (lower). Plasma ghrelin levels peaked in the 
early morning and decreased after meals. Plasma ghrelin lev-
els are shown based on a value calculated before breakfast 
on the morning of day 1 as 100. Plasma desacyl-ghrelin levels 
with formula resembled those with no formula administra-
tion, while single administration of formula between break-
fast and lunch induced higher acyl-ghrelin levels before 
dinner, remaining high until the next morning. Open circles, 
levels without administration of formula; closed circles, levels 
with administration of formula; closed squares administration 
of formula. Arrows show meal-taking for inpatients with 
chronic respiratory disease. Data are expressed as mean ± 
standard deviation. *, p < 0.05 for ghrelin level with vs. with-
out administration of formula.
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profiles during the study showed that the total level of
acyl-ghrelin and desacyl-ghrelin was high, but the ratio of
plasma acyl-ghrelin to desacyl-ghrelin was low in cachec-
tic CRD patients. High levels of ghrelin in cachectic
patients have been suggested to maintain energy balance
to prevent weight loss, consistent with previously studies
reporting an inverse correlation between BMI and plasma
ghrelin levels [7,8]. Acylation is necessary for ghrelin to
induce appetite and desacyl-ghrelin is likely to inhibit
appetite in mice [9], suggesting that the ratio of acylated
ghrelin to desacyl-ghrelin may be important in determin-
ing the orexigenic effects of ghrelin.
The present study showed that administration of formula
containing high levels of octanoic acids increased plasma
acyl-ghrelin levels along with weight in patients with
CRD. The study was designed for outpatients and exact
food intake including formula during the 2-week period
was not measured. Weight gain may have been due to the
additional energy provided by the formula in addition to
regular meals. In the present study, 2-week administration
of the formula induced an increase in both weight and
plasma acyl-ghrelin levels, suggesting that weight gain was
associated with increases in acyl-ghrelin and the orexi-
genic effect was due to decreased plasma ghrelin levels
when the patients displayed weight increases.
Additional induction of acyl-ghrelin induced a significant
increase in IGF-1 levels. The concentration of circulating
IGF-1 declines with age [10] and this hormone is involved
in physiological changes of aging such as increased cardi-
ovascular risk, reduced muscle mass and strength, reduced
exercise tolerance and impaired quality of life [11]. IGF-1
stimulates osteoblast proliferation as well as osteoclast
differentiation to inhibit osteopenia [12]. CRD with air-
flow obstruction has been shown to represent a causative
risk for osteoporosis [13], so elevation of IGF-1 levels may
be particularly useful for elderly individuals with CRD.
In conclusion, formula containing octanoic acids
increased body weight and plasma acyl-ghrelin levels.
This is the first trial showing a change in orexigenic hor-
mone among patients receiving nourishment treatment.
The present results seem likely to contribute to nutritional
management in patients with cachectic diseases.
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